Quark Pharmaceuticals, Inc. is a late-stage pharmaceutical company. It is a company that operates in the discovery and development of novel small interfering RNA (siRNA) therapeutics. The company's aim is to improve the lives of patients by harnessing the natural mechanism of siRNAs. By inhibiting vital disease-related genes, it believes it can address significant unmet medical needs that could not be thought about as curable before adventing siRNA therapies.
The company's late-stage pipeline includes siRNA therapies for renal protection in cardio-renal disease and neuroprotection in ophthalmology, with two products currently in Phase 3 clinical trials. Late- and early-stage pipeline products address multiple disease areas with considerable unmet medical needs, targeting different genes with proven delivery to multiple organs. With an investment that is well above US$700 million, Quark has generated more than 420 issued patents globally, where more than 80 were granted in the United State and Europe.